UI Hospitals and Clinics
Randomized Phase II Study of AB (Abraxane, Bevacizumab) versus Ipilimumab for 1st Line Therapy of Unresectable Stage IV Metastatic Malignant Melanoma (BRAF V600E Negative)
Participants in this research study have Unresectable Stage IV Metastatic Malignant Melanoma (BRAF V600E Negative). Participants will receive either the drugs nab-paclitaxel( Abraxane®) and bevacizumab (Avastin®) or the commonly-used drug ipilimumab. The purpose of this study is to compare whether the study drugs nab-paclitaxel and bevacizumab keep cancer from getting worse for a longer period of time. Approximately 16 people will take part in this study conducted by investigators at the University of Iowa. Up to 176 people will take part in this study at approximately 11 sites in the Midwest Melanoma Partnership group.
Melanie Frees 319-356-1228
We welcome your feedback! Please help us improve your experience on our website by completing a brief survey.